Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-12-02Clinical Trial Update: Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy [Phase 4]
Phase 4 trial comparing revascularization versus medical therapy for ischemic nephropathy due to renal artery stenosis; the current status o…
-
CLINICAL_TRIALS trial_result · 2009-12-01Clinical Trial Update: A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension [Phase 2]
A Phase 2 study comparing eplerenone with losartan for mild-to-moderate hypertension has been terminated.
-
CLINICAL_TRIALS research · 2009-12-01Clinical Trial Update: Effect of Lateral Pharyngoplasty on Blood Pressure in Obstructive Sleep Apnea (OSA) Patients [NA]
A clinical trial update assessing whether lateral pharyngoplasty affects blood pressure in patients with obstructive sleep apnea.
-
CLINICAL_TRIALS trial_result · 2009-11-30Clinical Trial Update: The Pharmacokinetics of Nifedipine Controlled Release Tablets in Hypertensive Patients on Hemodialysis [Phase 4]
Phase 4 pharmacokinetic update of nifedipine controlled-release tablets in hypertensive patients on maintenance hemodialysis.
-
EMA withdrawal · 2009-11-26EMA Withdrawn: Irbesartan BMS (irbesartan) — Bristol-Myers Squibb Pharma EEIG
The EMA withdrew the irbesartan product Irbesartan BMS (irbesartan) from Bristol-Myers Squibb Pharma EEIG, affecting its hypertension therap…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2009-11-24EMA Withdrawn: Irbesartan Hydrochlorothiazide BMS (irbesartan;hydrochlorothiazide) — Bristol-Myers Squibb Pharma EEIG
The EMA withdrawal of irbesartan/hydrochlorothiazide (BMS) from the European market in 2009.
-
CLINICAL_TRIALS research · 2009-11-23Clinical Trial Update: Simvastatin in Patients With Isolated Arterial Hypertension
A clinical trial update explores simvastatin use in patients with isolated arterial hypertension. The trial status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2009-11-20Clinical Trial Update: Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance [Phase 2]
Phase 2 clinical trial evaluating a soluble epoxide hydrolase (s-EH) inhibitor in patients with hypertension and impaired glucose tolerance …
-
CLINICAL_TRIALS trial_result · 2009-11-18Clinical Trial Update: TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium
This completed Belgian observational study evaluated the real-world effectiveness of telmisartan for hypertension in patients with and witho…
-
FDA approval · 2009-11-18FDA Approved: LISINOPRIL — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for lisinopril from Quallent Pharmaceuticals Health LLC, approving this generic lisinopril product.
-
FDA approval · 2009-11-17FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Civica, Inc.)
FDA approved Civica, Inc.'s nicardipine hydrochloride as an original generic application (ANDA 090534), making a generic version of this cal…
-
FDA approval · 2009-11-17FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Lifestar Pharma LLC)
FDA approved the original application for nicardipine hydrochloride from Lifestar Pharma LLC, a generic version of the calcium channel block…
-
FDA approval · 2009-11-17FDA Approved: NICARDIPINE HYDROCHLORIDE — Original Application (Archis Pharma LLC)
FDA approved an original application for a generic NICARDIPINE HYDROCHLORIDE product from Archis Pharma LLC.
-
FDA approval · 2009-11-13FDA Approved: CATAPRES-TTS-1 — Supplemental Application (Technomed Inc.)
The FDA approved a supplemental application for CATAPRES-TTS-1, the clonidine transdermal system, from Technomed Inc., signaling regulatory …
-
FDA approval · 2009-11-10FDA Approved: BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for benazepril hydrochloride and hydrochlorothiazide, expanding the labeling for this fixed-dose com…
-
FDA approval · 2009-11-10FDA Approved: ALISKIREN — Supplemental Application (Prasco Laboratories)
FDA approves a supplemental application to allow Prasco Laboratories to market aliskiren hemifumarate.
-
CLINICAL_TRIALS trial_result · 2009-11-09Clinical Trial Update: The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial [Phase 3]
Phase 3 COSMOS trial evaluated the combination of carvedilol (COREG) and lisinopril in hypertensive subjects; results were posted after stud…
-
FDA label_change · 2009-11-06FDA Approved: ZESTORETIC — Supplemental Application (Almatica Pharma Inc.)
FDA approved a supplemental application for ZESTORETIC (lisinopril and hydrochlorothiazide) submitted by Almatica Pharma Inc. The supplement…
-
FDA approval · 2009-11-06FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for a generic fixed-dose combination of bisoprolol fumarate and hydrochlorothiazide, expanding avail…
-
CLINICAL_TRIALS trial_result · 2009-11-06Clinical Trial Update: A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk [Phase 4]
Phase 4 trial comparing a multi-risk factor strategy to guideline-based approach for achieving blood pressure and lipid goals in high-risk h…
-
CLINICAL_TRIALS research · 2009-11-05Clinical Trial Update: Cardiovascular Risk Factors After Renal Transplantation in Children and Adults
The trial update investigates cardiovascular risk factors in renal transplant recipients (children and adults), focusing on exercise capacit…
-
CLINICAL_TRIALS trial_result · 2009-11-03Clinical Trial Update: Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
A completed clinical trial from AstraZeneca assessed the impact of patient education on cardiovascular risk factors in individuals with type…
-
FDA approval · 2009-10-30FDA Approved: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
The FDA approved a supplemental application for Enalapril maleate and hydrochlorothiazide from Taro Pharmaceuticals U.S.A., Inc. to update t…
-
FDA approval · 2009-10-29FDA Approved: RAMIPRIL — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA granted supplemental approval for Lupin Pharmaceuticals’ ramipril generic under the ANDA, authorizing continued marketing of the product…
-
CLINICAL_TRIALS trial_result · 2009-10-29Clinical Trial Update: European Study of Cardiovascular Risk
A European cardiovascular risk trial sponsored by AstraZeneca has completed, focusing on cardiovascular risk factors and hyperlipidemia.